Bpifrance takes 1.8% equity stake in Opella (Doliprane maker) alongside CD&R/Sanofi close

Mechanism

Opella (Doliprane, Dulcolax, Allegra and other OTC brands) was carved out of Sanofi in 2024-25 amid sustained French political controversy over losing domestic control of a company seen as essential to the country's paracetamol/OTC medicine supply chain — a sensitivity sharpened by pandemic-era shortages. Sanofi agreed in October 2024 to sell a 50% controlling stake to CD&R; the deal closed 30 April 2025. As part of closing, Bpifrance — the French state's public investment and industrial-policy bank — took a 1.8% stake alongside a board seat, with Sanofi retaining 48.2%. Bpifrance CEO Nicolas Dufourcq framed the investment as backing Opella "to make the company a worldwide champion of consumer health based in France."

The stake itself is financially small (1.8%), so severity is set low (2) — this is not a blocking or golden-share mechanism, and the board seat confers influence rather than control. It is filed as industrial-policy rather than investment-screening because no formal screening veto or conditionality was publicly disclosed; the state's leverage here is a minority equity position negotiated alongside the deal, not a statutory review outcome.

Severity rationale

Severity is anchored on the disclosed stake size: Bpifrance took 1.8% of Opella's share capital (source: Bpifrance press release, 30 April 2025), against a €10bn total transaction and a controlling 50% stake going to CD&R. A single-digit minority position with one board seat and no disclosed veto or golden-share rights is a low-intensity industrial-policy instrument — hence severity 2, not the 3-4 range reserved for blocking/conditional FDI-screening outcomes. No tariff/quota/coverage figure applies to this action type, so no magnitude: block is filed; the quant anchor is the equity percentage cited above and in the summary.

Downstream implications

• Signals the continued use of Bpifrance minority stakes as a soft-sovereignty

tool in politically sensitive foreign-control transactions in strategic consumer/health manufacturing, distinct from formal FDI-screening blocks.

• Board seat gives the French state visibility into Opella's manufacturing

and site-location decisions (13 sites, 11,000+ employees) going forward.

Open questions

• Investment amount in euros was not disclosed in the Bpifrance release;

watch for disclosure in Bpifrance's 2025 annual report.

• Whether any side-letter commitments on French manufacturing/employment

levels were attached to the stake (none surfaced in primary or secondary sources reviewed).